SCHEMBL5111773

SCHEMBL5111773

COc1cc(C)c(S(=O)(=O)N(C)CCCCC(=O)N(C)Cc2ccc(C3=NCCN3C(=O)O)cc2)c(C)c1

nearest known ligand 0.53

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
BDKRB1 P46663 19/20 0.53
BCHE P06276 1/20 0.39
ACHE P22303 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5125808 0.94 BDKRB1 (0.55) BDKRB1
SCHEMBL5119278 0.91 BDKRB1 (0.54) BDKRB1BCHEACHE
SCHEMBL5115128 0.89 BDKRB1 (0.43) BDKRB1
SCHEMBL5124693 0.88 BDKRB1 (0.69) BDKRB1
SCHEMBL5111789 0.85 BDKRB1 (0.43) BDKRB1
SCHEMBL5114090 0.85 BDKRB1 (0.55) BDKRB1BCHEACHE
SCHEMBL5114361 0.84 BDKRB1 (0.50) BDKRB1BCHEACHE
SCHEMBL5114280 0.83 BDKRB1 (0.45) BDKRB1BCHEACHE
SCHEMBL5118248 0.83 BDKRB1 (0.43) BDKRB1BCHEACHE
SCHEMBL5124683 0.82 BDKRB1 (0.49) BDKRB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7361687-B2 Arylsulphonamide derivatives and methods of preparing LABORATOIRES FOURNIER SA (FR) 2008-04-22 US disclosed
US-20060084699-A1 Novel arylsulphonamide derivatives and use thereof as therapeutic agents LABORATOIRES FOURNIER SA (FR) 2006-04-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060084699-A1 Novel arylsulphonamide derivatives and use thereof as therapeutic agents UGT1A1, UGT2B7, UGT1A6 BDKRB1 1217/4885BCHE 3422/4885ACHE 4862/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.